ALISO VIEJO, Calif., Nov. 22, 2017 /PRNewswire/ --RxSight, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the RxSight™ Light Adjustable Lens and the Light Delivery ...

Please provide your email address to receive an email when new articles are posted on . TAMPA, Fla. — The Light Adjustable Lens optimizes postoperative results after cataract surgery, a speaker said ...

The best thing about cataract surgery is corrected vision, of course. It’s a topic Paula knows all-too-well after having cataract surgery last summer which totally corrected her vision to the point ...

Please provide your email address to receive an email when new articles are posted on . The top-performing videos from Cataract Surgery: Telling It Like It Is include new perspectives on the Light ...

ALISO VIEJO, Calif. - RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, has announced the commercial release of its latest product, the Light Adjustable Lens+ (LAL+), designed to ...

Eye Surgeons Associates is the first practice in Iowa to offer the Light-Adjustable Lens (LAL) by RxSight to cataract patients. Cataracts occur when the eye’s natural lens becomes clouded and rigid, ...

ALISO VIEJO, Calif. , April 19, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST)-- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, ...

ST. LOUIS, MO / ACCESSWIRE / December 18, 2019 / Brinton Vision, a leading St. Louis LASIK and vision correction practice, has become the first eye surgery center in the state of Missouri to offer the ...

Nearly three million cataract surgeries are performed every year in the United States. The majority of patients must wear prescription glasses after the procedure to see properly. But a new technology ...

The Light Adjustable Lens (LAL) is the only IOL that enables you and your doctor to design, trial, and customize your vision after cataract surgery. Adjustability takes cataract surgery to the next ...

台湾の医療保険請求に基づく研究データベース（Taiwan National Health Insurance Research Database）に登録された白内障手術施行患者18万6591例を対象に、ブルーライトカット眼内レンズ（BF-IOL）による術後の加齢黄斑変性（AMD）抑制効果を全国コホート研究で検討した。

H&Iグローバルリサーチ株式会社（本社：東京都中央区）は、この度、MarketsandMarketsが発行した「眼内レンズ（IOL）の世界市場予測（～2022年）」調査資料の取扱・販売をMarketReport.jpサイト（www.MarketReport.jp、取扱レポート数は日本最大級）にて開始しました。